EU doctors turn to last-ditch antibiotics as resistance grows
There are few new antibiotics on the horizon and experts are worried that only a few big drug firms, such as GlaxoSmithKline and AstraZeneca, still have strong antibiotic research and development programmes.
Robert-Jan Smits, director-general for research and innovation at the European Commission, said the worrying growth of antibiotic resistance ... calls for a dedicated research effort. He added that the Commission had put more money this year than ever into research on resistance.
Be the first to comment.